NEPA is named as an intervention in 3 current clinical trials in our China, Italy, Poland and Turkey registers. 3 are recruiting patients now. The most common phase is Observational. The sponsor with the most trials is Tianjin Medical University Cancer Institute and Hospital (1). The most-studied condition is General Anesthesia Gastrointestinal Cancer Surgery.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Akynzeo as Antiemetic Treatment in Patients With Endometrial Cancer
NCT06726291 · ClinicalTrials.gov ↗ · Endometrial Cancer
|
Phase 4 | Recruiting | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Italy |
|
Study With IV NEPA (Fosnetupitant/Palonosetron) for the Prevention of Chemotherapy-induced Nausea and Vomiting in Paediatric Cancer Patients Undergoing Highly Emetogenic Chemotherapy (HEC)
NCT06904235 · ClinicalTrials.gov ↗ · Nausea and Vomiting Chemotherapy-Induced, Nausea Post Chemotherapy
|
Phase 2 | Recruiting | Helsinn Healthcare SA | Poland, Turkey |
|
The Safety and Effectiveness of NEPA in Preventing Postoperative Nausea and Vomiting After General Anesthesia Gastrointestinal Cancer Surgery: A Single-Center Retrospective Study
NCT06417567 · ClinicalTrials.gov ↗ · General Anesthesia Gastrointestinal Cancer Surgery
|
Observational | Recruiting | Tianjin Medical University Cancer Institute and Hospital | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Tianjin Medical University Cancer Institute and Hospital | 1 |
| Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 1 |
| Helsinn Healthcare SA | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 1 | 1 |
| Clinical trials in Italy | 1 | 1 |
| Clinical trials in Poland | 1 | 1 |
| Clinical trials in Turkey | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
3 current trials in our China, Italy, Poland and Turkey registers name NEPA as a drug or biological intervention, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 3 of the 3 trials are recruiting: 1 with sites in China, 1 with sites in Italy, 1 with sites in Poland and 1 with sites in Turkey. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Tianjin Medical University Cancer Institute and Hospital (1), Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (1) and Helsinn Healthcare SA (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how NEPA works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how NEPA works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists NEPA (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 26 Sep 2026.